345 related articles for article (PubMed ID: 18073778)
1. Cathepsin K inhibitors: a novel target for osteoporosis therapy.
Stoch SA; Wagner JA
Clin Pharmacol Ther; 2008 Jan; 83(1):172-6. PubMed ID: 18073778
[TBL] [Abstract][Full Text] [Related]
2. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats.
Kim MK; Kim HD; Park JH; Lim JI; Yang JS; Kwak WY; Sung SY; Kim HJ; Kim SH; Lee CH; Shim JY; Bae MH; Shin YA; Huh Y; Han TD; Chong W; Choi H; Ahn BN; Yang SO; Son MH
J Pharmacol Exp Ther; 2006 Aug; 318(2):555-62. PubMed ID: 16699068
[TBL] [Abstract][Full Text] [Related]
3. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.
Stroup GB; Lark MW; Veber DF; Bhattacharyya A; Blake S; Dare LC; Erhard KF; Hoffman SJ; James IE; Marquis RW; Ru Y; Vasko-Moser JA; Smith BR; Tomaszek T; Gowen M
J Bone Miner Res; 2001 Oct; 16(10):1739-46. PubMed ID: 11585335
[TBL] [Abstract][Full Text] [Related]
4. Changes in micro-CT 3D bone parameters reflect effects of a potent cathepsin K inhibitor (SB-553484) on bone resorption and cortical bone formation in ovariectomized mice.
Xiang A; Kanematsu M; Kumar S; Yamashita D; Kaise T; Kikkawa H; Asano S; Kinoshita M
Bone; 2007 May; 40(5):1231-7. PubMed ID: 17347064
[TBL] [Abstract][Full Text] [Related]
5. 6. Cathepsin K inhibitors: their potential as anti-osteoporosis agents.
Deaton DN; Kumar S
Prog Med Chem; 2004; 42():245-375. PubMed ID: 15003723
[No Abstract] [Full Text] [Related]
6. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics.
Yasuda Y; Kaleta J; Brömme D
Adv Drug Deliv Rev; 2005 May; 57(7):973-93. PubMed ID: 15876399
[TBL] [Abstract][Full Text] [Related]
7. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
[TBL] [Abstract][Full Text] [Related]
8. Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
Lewiecki EM
IDrugs; 2009 Dec; 12(12):799-809. PubMed ID: 19943223
[TBL] [Abstract][Full Text] [Related]
9. The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice.
Yamane H; Sakai A; Mori T; Tanaka S; Moridera K; Nakamura T
Bone; 2009 Jun; 44(6):1055-62. PubMed ID: 19303837
[TBL] [Abstract][Full Text] [Related]
10. Cathepsin K inhibitor-polymer conjugates: potential drugs for the treatment of osteoporosis and rheumatoid arthritis.
Wang D; Li W; Pechar M; Kopecková P; Brömme D; Kopecek J
Int J Pharm; 2004 Jun; 277(1-2):73-9. PubMed ID: 15158970
[TBL] [Abstract][Full Text] [Related]
11. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
Le Gall C; Bellahcène A; Bonnelye E; Gasser JA; Castronovo V; Green J; Zimmermann J; Clézardin P
Cancer Res; 2007 Oct; 67(20):9894-902. PubMed ID: 17942921
[TBL] [Abstract][Full Text] [Related]
12. Structure-based development of pyridoxal propionate derivatives as specific inhibitors of cathepsin K in vitro and in vivo.
Katunuma N; Matsui A; Inubushi T; Murata E; Kakegawa H; Ohba Y; Turk D; Turk V; Tada Y; Asao T
Biochem Biophys Res Commun; 2000 Jan; 267(3):850-4. PubMed ID: 10673380
[TBL] [Abstract][Full Text] [Related]
13. Cathepsin K, osteoclastic resorption, and osteoporosis therapy.
Zaidi M; Troen B; Moonga BS; Abe E
J Bone Miner Res; 2001 Oct; 16(10):1747-9. PubMed ID: 11585336
[No Abstract] [Full Text] [Related]
14. Recent developments in cathepsin K inhibitor design.
Grabowskal U; Chambers TJ; Shiroo M
Curr Opin Drug Discov Devel; 2005 Sep; 8(5):619-30. PubMed ID: 16159024
[TBL] [Abstract][Full Text] [Related]
15. Cathepsin K inhibitors: a novel target but promising approach in the treatment of osteoporosis.
Helali AM; Iti FM; Mohamed IN
Curr Drug Targets; 2013 Dec; 14(13):1591-600. PubMed ID: 23957815
[TBL] [Abstract][Full Text] [Related]
16. Different cysteine proteinases involved in bone resorption and osteoclast formation.
Brage M; Abrahamson M; Lindström V; Grubb A; Lerner UH
Calcif Tissue Int; 2005 Jun; 76(6):439-47. PubMed ID: 15906014
[TBL] [Abstract][Full Text] [Related]
17. Future therapeutic targets in osteoporosis.
Deal C
Curr Opin Rheumatol; 2009 Jul; 21(4):380-5. PubMed ID: 19461517
[TBL] [Abstract][Full Text] [Related]
18. Identification of a nonbasic, nitrile-containing cathepsin K inhibitor (MK-1256) that is efficacious in a monkey model of osteoporosis.
Robichaud J; Black WC; Thérien M; Paquet J; Oballa RM; Bayly CI; McKay DJ; Wang Q; Isabel E; Léger S; Mellon C; Kimmel DB; Wesolowski G; Percival MD; Massé F; Desmarais S; Falgueyret JP; Crane SN
J Med Chem; 2008 Oct; 51(20):6410-20. PubMed ID: 18811135
[TBL] [Abstract][Full Text] [Related]
19. A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.
Lark MW; Stroup GB; James IE; Dodds RA; Hwang SM; Blake SM; Lechowska BA; Hoffman SJ; Smith BR; Kapadia R; Liang X; Erhard K; Ru Y; Dong X; Marquis RW; Veber D; Gowen M
Bone; 2002 May; 30(5):746-53. PubMed ID: 11996914
[TBL] [Abstract][Full Text] [Related]
20. Cystatin B as an intracellular modulator of bone resorption.
Laitala-Leinonen T; Rinne R; Saukko P; Väänänen HK; Rinne A
Matrix Biol; 2006 Apr; 25(3):149-57. PubMed ID: 16321512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
